Introduction {#s1}
============

Despite the remarkable advances in the management and treatment of cancer patients over the years, cancer continues to be a major public health issue and there are many problems remaining to be solved ([@B1], [@B2]). It is estimated that new cases of cancer will be as many as 18.1 million while cancer deaths worldwide will be up to 9.6 million in 2018 ([@B3]). As new cases and deaths from cancer increase annually, it is expected that the burden of cancer will aggravate in tandem, especially in less developed countries ([@B4]). Since the diagnosis of various cancers is confirmed at advanced stages rather than the early stages, the prognosis of cancer is poor. Therefore, identification and validation of novel applicable cancer biomarkers with high sensitivity and specificity are crucial for predicting prognosis and performing targeted therapy ([@B5]). Clinicians may use some potential prognostic biomarkers to make an early diagnosis and choose the optimal therapeutic schedule.

The long non-coding RNAs (lncRNAs) are a new category of non-coding RNAs measuring more than 200 nucleotides in length, lacking the ability to encode any protein ([@B6]). The genome-wide studies have shown that the majority of the human genome are dynamically transcribed to create a large portion of lncRNAs ([@B7]). Increasing evidence has been provided by the application of next-generation sequencing technologies for lncRNA dysregulation in cancer. Accumulating evidence indicates that lncRNAs exert synergetic functions on tumorigenesis or tumor suppression, and abnormal expression of lncRNAs may respond to cell proliferation, tumor progression or metastasis ([@B8], [@B9]). LncRNAs are functionally categorized into two major categories of tumor suppressors and oncogenes ([@B10]). As shown from previous studies, lncRNAs might act as transcriptional regulators, splicing modulators, enhancers, post-transcriptional processors, scaffolds, or molecular decoys by interacting physically with proteins or other types of RNA, thereby directly affecting the cellular signaling cascades ([@B11], [@B12]). Functional lncRNAs were identified as promising biomarkers for diagnosing cancer and predicting tumor prognosis, and could also be utilized as potential therapeutic targets ([@B13]).

PANDAR (promoter of CDKN1A antisense DNA damage activated RNA), initially reported by Hung et al. is an emerging noncoding RNA with 1,506 nucleotides in length mapping to chromosome 6p21.2 ([@B14]). As discovered by Hung et al. PANDAR is induced after DNA damage in a p53-dependent pattern, limiting the expression of pro-apoptotic genes in fibroblasts by interacting with the transcription factor NF-YA ([@B14]). Recently, PANDAR was known as biomarkers of cancer and potentially involved in the instability of chromosomes and cancer metastatic progression ([@B15], [@B16]). It was found in previous studies that PANDAR was upregulated in various cancers, including gastric cancer ([@B17]), cholangiocarcinoma ([@B18]), hepatocellular carcinoma ([@B19]), and clear cell renal cell carcinoma ([@B20]). On the other hand, it was downregulated with poor prognosis in non-small cell lung cancer ([@B21]). The obvious tissue-specific expression patterns of lncRNA relative to protein-coding genes may result in the inconsistent expression of PANDAR in cancer ([@B22], [@B23]). In conclusion, there is still controversy about the prognostic value of PANDAR in cancer patients due to the distinct outcome and limited sample size in most studies reported to date. Hence, we conducted a current and comprehensive meta-analysis to elucidate the prognosis and clinicopathological significance of PANDAR expression in patients diagnosed as cancer.

Materials and Methods {#s2}
=====================

Study Strategy
--------------

All procedures mentioned below were performed in accordance with PRISMA Checklist and Cochrane Collaboration protocols ([@B24], [@B25]). Two researchers (Lizhi Han and Bo Wang) searched the databases PubMed, SinoMed, Embase, and Web of Science independently to collect all articles associated with the prognostic value of aberrantly expressed PANDAR in malignancy patients. The literature search was completed on November 11, 2018. The detailed example of the full electronic search strategy for PubMed is provided in [Supplementary Material 1](#SM1){ref-type="supplementary-material"}. In order to heighten the sensitivity of the search, both free-text words and MeSH terminology were utilized in the search strategy. The search strategy included: "PANDAR or long non-coding RNA PANDAR, human" AND "tumor or cancer or neoplasm or carcinoma or malignancy" AND "prognosis or prognostic or outcome or survival." The references of articles collected for our study were screened to obtain the eligible literature. There were discussions among the groups to settle any conflicts.

Inclusion and Exclusion Criteria
--------------------------------

Studies that complied with the following criteria were eventually included: (1) Study design: case-control study; (2) Population: patients were pathologically diagnosed with any type of human malignancy; (3) Intervention and Comparison: patients were divided into negative and positive expression or low and high expression group according to the expression levels of PANDAR, the patients whose expression levels of PANDAR are positive or high belong to intervention group while the patients whose expression levels of PANDAR are negative or low belong to comparison group. Any applicable techniques were used to measure the expression level of lncRNA-PANDAR in human tissues; (4) Outcomes: the connection between PANDAR expression level and survival outcome was examined including overall survival and event-free survival; (5) Sufficient published data or the survival curves were provided to calculate HRs for survival rates and their 95% confidence intervals (CIs). The eliminated criteria were as follows: (1) Repeated or overlapped articles; (2) Case-reports and reviews; (3) Inadequate original data of survival analysis. If the original article was not available for extracting or assessing data, the study was excluded. Two researchers (Lizhi Han and Bo Wang) screened all eligible studies elaborately, and a third researcher (Song Gong) was consulted to resolve any differences.

Data Extraction
---------------

Two (Lizhi Han and Bo Wang) independently extracted related data and came to an agreement on all items. In order to obtain all qualified studies, the author, year of publication, tumor type, expression associated with poor prognosis, method of obtaining HRs, Newcastle--Ottawa Scale (NOS) score, and special information about the study population \[such as number of patients (high/low), country of the population enrolled, follow up (month)\], detection method, endpoints, survival analysis and cut-off value of all articles were collected. Overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were all considered as endpoints. HR was extracted according to the previously proposed methodology to assess the impact of PANDAR expression on the prognosis of patients ([@B26]). We also inquired original data from the authors if they allowed.

Quality Assessment
------------------

Quality of all included studies was evaluated independently by two researchers(Lizhi Han and Bo Wang) using the Newcastle-Ottawa Scale ([@B27]). There were totally three categories within the scale including selection, comparability, and outcome, with a full-mark of nine. Studies were identified as high-quality in methodology with at least six scores.

Statistical Analysis
--------------------

Stata Software 14.0 (Stata, College Station, TX) was used for quantitative calculation. For evaluating the prognostic value of PANDAR expression in different types of malignancies, pooled HRs (high/low) together with their related 95% CIs were applied. For analyzing the correlation between PANDAR expression levels and clinicopathological parameters, pooled ORs (high/low) and their related 95% CIs were utilized. Cochran\'s Q and *I*^2^ statistics were used to assess the heterogeneity among the included studies ([@B28]). An *I*^2^ value larger than 50% or a *p*-value lower than 0.10 was regarded as statistically significant. An insignificant heterogeneity (*p* \> 0.01, *I*^2^ \< 50%) was adjusted by a fixed-effects model for analysis, otherwise, a random-effects model was selected. Subgroup analysis and meta-regression were conducted to explore the source of heterogeneity. In addition, we could acquire clinicopathological characteristics from the studies, and figured out the pooled ORs and performed heterogeneity tests in order to analyze the relationship between PANDAR expression levels with tumor stages, tumor size, lymph node metastasis, gender, age, depth of invasion, differentiation grade, and distant metastasis in different kinds of cancers. Moreover, in order to check the stability of pooled outcomes, a sensitivity analysis was conducted. Both Begg\'s test and Egger\'s test were used for assessing publication bias ([@B29]). The statistical significance within all comparisons was mathematically signified as *P* \< 0.05.

Results {#s3}
=======

Characteristics of Studies
--------------------------

Thirteen studies were selected from the 73 articles initially searched, which consists of 13 retrospective cohorts. [Figure 1](#F1){ref-type="fig"} shows the screening procedure and results in our study, according to PRISMA guideline ([@B27]). There were 1,465 patients involved in those studies, with 31 being the minimum sample size, and 482 being the largest. The accrual period was between 2015 and 2018. The enrolled studies were composed of ten types of cancers, including renal cell carcinoma (*n* = 2), colorectal cancer (*n* = 2), non-small cell lung cancer (*n* = 2), cervical squamous cell carcinoma (*n* = 1), gastric cancer (*n* = 1), cholangiocarcinoma (*n* = 1), hepatocellular carcinoma (*n* = 1), pancreatic ductal adenocarcinoma (*n* = 1), bladder cancer (*n* = 1), and oral squamous cell carcinoma (*n* = 1). OS, DFS, and PFS were reckoned as survival outcome, referring to 85% (11/13), 7% (1/13), and 7% (1/13), respectively, among these studies. In our study, EFS was derived from the combination of DFS and PFS, which was considered as a prognostic parameter. The lncRNA PANDAR expression levels were mainly measured using western blot (WB), real-time PCR (RT-PCR) and immunohistochemistry (IHC). Among these studies, the cut-off values were different due to various cut-off definitions. Further details about baseline features were recorded in [Table 1](#T1){ref-type="table"}.

![The selection flow chart of our systematic review.](fonc-09-01337-g0001){#F1}

###### 

Characteristics of studies included in the meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**               **Region**   **Tumor type**                     **Detection method**   **Sample size**\   **Follow-up**\   **Endpoints**   **Expression associated with poor prognosis**   **Cut-off value**        **NOS score**   **Method**
                                                                                                 **(high/low)**     **(month)**                                                                                                               
  ----------------------- ------------ ---------------------------------- ---------------------- ------------------ ---------------- --------------- ----------------------------------------------- ------------------------ --------------- ------------
  Huang et al. ([@B30])   China        Cervical squamous cell carcinoma   qRT-PCR                38/30 (68)         48               OS              High                                            High: fold change\>4.7   6               1

  Jiang et al. ([@B31])   China        Pancreatic ductal adenocarcinoma   qRT-PCR\               17/14 (31)         NA               OS              High                                            NA                       6               2
                                                                          WB                                                                                                                                                                  

  Han et al. ([@B21])     China        Non-small cell lung cancer         qRT-PCR\               70/70 (140)        60               OS              Low                                             Mean                     6               1
                                                                          WB\                                                                                                                                                                 
                                                                          IHC                                                                                                                                                                 

  Lu et al. ([@B32])      China        Colorectal cancer                  qRT-PCR\               62/62 (124)        60               OS              High                                            Median                   6               1
                                                                          WB                                                                                                                                                                  

  Ma et al. ([@B17])      China        Gastric cancer                     qRT-PCR                73/27 (100)        36               OS, DFS         High                                            NA                       7               1

  Peng and Fan ([@B19])   China        Hepatocellular carcinoma           qRT-PCR                326/156 (482)      60               OS, TTR         High                                            NA                       7               2

  Li et al. ([@B17])      China        Colorectal cancer                  qRT-PCR                51/51 (102)        60               OS              High                                            Median                   7               1

  Xu et al. ([@B20])      China        Renal cell carcinoma               qRT-PCR\               34/28 (62)         40               OS              High                                            Median                   6               1
                                                                          WB                                                                                                                                                                  

  Xu et al. ([@B18])      China        Cholangiocarcinoma                 qRT-PCR\               40/27 (67)         60               OS              High                                            NA                       7               1
                                                                          WB                                                                                                                                                                  

  Zhan et al. ([@B33])    China        Bladder cancer                     qRT-PCR                37/18 (55)         NA               OS              High                                            Mean                     6               2

  Jin ([@B34])            China        Renal cell carcinoma               qRT-PCR                22/26 (48)         60               OS              High                                            NA                       7               2

  Huang et al. ([@B35])   China        Oral squamous cell carcinoma       qRT-PCR                47/45 (92)         60               OS              High                                            NA                       7               1

  Nie et al. ([@B36])     China        Non-small cell lung cancer         qRT-PCR                27/67 (94)         48               OS, PFS         Low                                             NA                       6               2
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Method: 1 denoted as obtaining HRs directly from publications; 2 denoted as HRs calculated from the total number of events, corresponding p-value and data from Kaplan--Meier curves; IHC, immunohistochemistry; PCR, polymerase chain reaction; WB, western blot; OS, overall survival; TTR, time to recurrence; DFS, disease-free survival; NOS, Newcastle--Ottawa Scale; NA, not available*.

Methodological Assessment
-------------------------

The majority of included trials were graded as high-quality in methodology, including six 7-score studies and seven 6-score studies. The detailed scores of each study by the Newcastle-Ottawa Scale were concluded in [Supplementary Material 2](#SM1){ref-type="supplementary-material"}.

Association Between lncRNA PANDAR Expression Levels With OS of Cancer Patients
------------------------------------------------------------------------------

Eleven studies consisting of 1,379 cancer patients reported the association between aberrant expression levels of lncRNA PANDAR with OS. The pooled HR was calculated using the random-effect model. Through detailed calculation, the pooled HR for OS was 1.72 (95%CI 1.14--2.60, *p* = 0.009), indicating the significant relationship between the high expression level of PANDAR with poor OS in malignancy patients ([Figure 2](#F2){ref-type="fig"}). To investigate the source of significant heterogeneity among these studies (*I*^2^ = 79.4%, *p* \< 0.001), subgroup analysis was further performed according to the following factors: type of cancer (non-digestive system or digestive system carcinoma), follow-up time (more than 60 or fewer than 60 months), sample size (more than 100 or fewer than 100), and paper quality (NOS scores ≥ 7 or \< 7) ([Figures 3A--D](#F3){ref-type="fig"}). The result of subgroup analysis demonstrated that the relationship between increased PANDAR expression levels with poor OS of cancer patients was still significant in all above factors apart from the subgroup of studies for non-digestive system carcinoma (HR 1.32, 95% CI 0.68--2.56, *p* = 0.419), follow-up time fewer than 60 months (HR 1.61, 95% CI 0.68--3.81, *p* = 0.275), and NOS scores \<7 (HR 1.56, 95% CI 0.76--3.20, *p* = 0.230) ([Table 2](#T2){ref-type="table"}). In order to further explore the sources of heterogeneity, we conducted meta-regression through the covariates which also consisted of the above factors. However, the results that *p* values \< 0.05 were not observed in the above covariates through meta-regression. This suggests that all above-mentioned factors were not the sources of heterogeneity ([Table 2](#T2){ref-type="table"}). In addition, we performed Cox multivariate analysis in nine studies including nine cohorts, finding that elevated expression level of PANDAR was an independent prognostic factor for OS in these cancer patients (HR 1.94, 95% CI 1.25--3.02, *p* = 0.003).

![Meta-analysis of the pooled HR of OS for malignancy patients.](fonc-09-01337-g0002){#F2}

![Results of subgroup analysis of pooled HR of OS for malignancy patients. **(A)** Subgroup analysis stratified by type of cancer. **(B)** Subgroup analysis stratified by sample size. **(C)** Subgroup analysis stratified by follow-up time. **(D)** Subgroup analysis stratified by NOS score.](fonc-09-01337-g0003){#F3}

###### 

Subgroup analysis of pooled HRs for OS in cancer patients with abnormal expression level of lncRNA PANDAR.

  --------------------------------------------------------------------------------------------------------------------------------------------
  **Subgroup analysis**               **No. of cohorts**   **Pooled OR\          **Meta regression (*p* value)**   **Heterogeneity**   
                                                           Random**                                                                    
  ----------------------------------- -------------------- --------------------- --------------------------------- ------------------- -------
  Type of cancer                                                                 0.167                                                 

     Non-digestive system carcinoma   6                    1.32 \[0.68--2.56\]   --                                80.8                0.000

     Digestive system carcinoma       5                    2.25 \[1.46--3.45\]   --                                58.7                0.046

  Sample size                                                                    0.791                                                 

     ≥100                             5                    1.87 \[0.96--3.62\]   --                                88.0                0.000

     \<100                            6                    1.64 \[0.96--2.80\]   --                                63.4                0.018

  NOS scores                                                                     0.534                                                 

     ≥7                               5                    1.63 \[1.31--2.03\]   --                                00.0                0.453

     \<7                              6                    1.56 \[0.76--3.20\]   --                                88.0                0.000

  Follow-up time                                                                 0.786                                                 

     \<60                             4                    1.61 \[0.68--3.81\]   --                                75.8                0.006

     ≥60                              7                    1.80 \[1.08--3.00\]   --                                83.4                0.000
  --------------------------------------------------------------------------------------------------------------------------------------------

Association Between lncRNA PANDAR Expression Levels With EFS of Cancer Patients
-------------------------------------------------------------------------------

Two studies in total, involving 194 patients, reported the effect of abnormally expressed PANDAR on DFS or PFS in cancer patients. In this current meta-analysis, DFS and PFS were defined as EFS. However, the outcome revealed no difference in predicting event-free survival (EFS) between the high and low expression of PANDAR (HR 1.03, 95% CI 0.20--5.22, *p* = 0.972) ([Figure 4](#F4){ref-type="fig"}). Take the limited number of included studies into consideration, the subgroup analysis to explore the sources of heterogeneity was not performed.

![Meta-analysis of the pooled HR of EFS for malignancy patients.](fonc-09-01337-g0004){#F4}

Association Between lncRNA PANDAR Expression Levels With OS of Certain Types of Cancers
---------------------------------------------------------------------------------------

The prognostic value of PANDAR in various cancers was further evaluated. According to the results of systemic analysis, high PANDAR expression was related to reduced OS in colorectal cancer (HR 3.43; 95% CI 2.06--5.72, *p* \< 0.001) ([Figure 5A](#F5){ref-type="fig"}) and low expression level of PANDAR was significantly associated with poor OS in non-small cell lung cancer (pooled HR 0.65, 95%CI 0.45--0.88, *p* = 0.006) ([Figure 5B](#F5){ref-type="fig"}). However, no significant association was noticed between the expression level of PANDAR and OS of patients suffering from renal cell carcinoma (HR 1.19; 95% CI 0.56--2.50, *p* = 0.655) ([Figure 5C](#F5){ref-type="fig"}).

![Meta-analysis of the pooled HR of OS for colorectal cancer **(A)**, renal cell carcinoma **(B)**, and non-small cell lung cancer **(C)**.](fonc-09-01337-g0005){#F5}

Association Between lncRNA PANDAR Expression Levels With Clinicopathological Characteristics of Cancer Patients
---------------------------------------------------------------------------------------------------------------

Analysis of the association between the expression levels of PANDAR and clinicopathological characteristics of cancer patients was illustrated in [Table 3](#T3){ref-type="table"}. The results of meta-analysis indicated that higher PANDAR expression levels were significantly associated with advanced tumor stage (OR = 2.05, 95% CI 0.99--4.27, *p* = 0.045) ([Figure 6F](#F6){ref-type="fig"}), deeper depth of invasion (OR = 3.95, 95% CI 2.35--6.63, *p* \< 0.001) ([Figure 6G](#F6){ref-type="fig"}), more lymph node metastasis (OR = 1.92, 95% CI 0.93--3.98, *p* = 0.049) ([Figure 6E](#F6){ref-type="fig"}), and farther distant metastasis (OR = 2.87, 95% CI 1.60--5.16, *p* \< 0.001) ([Figure 6H](#F6){ref-type="fig"}). However, no evidential relation was observed between elevated expression level of PANDAR with the older age (OR = 1.05, 95% CI 0.84--1.33, *p* = 0.649) ([Figure 6A](#F6){ref-type="fig"}), gender (OR = 0.98, 95% CI 0.76--1.26, *p* = 0.879) ([Figure 6B](#F6){ref-type="fig"}), larger tumor size (OR = 1.28, 95% CI 0.73--2.25, *p* = 0.386) ([Figure 6C](#F6){ref-type="fig"}), and worse differentiation grade (OR = 1.45, 95% CI 0.95--2.21, *p* = 0.082) ([Figure 6D](#F6){ref-type="fig"}).

###### 

Association between lncRNA PANDAR and clinicopathological characteristics of cancer patients.

  **Clinicopathological parameters**                      **Studies (*n*)**   **Patients (*n*)**   **OR (95% CI)**     ***P* value**   **Heterogeneity**           
  ------------------------------------------------------- ------------------- -------------------- ------------------- --------------- ------------------- ------- --------
  Age (\>60 vs. ≤ 60 years)                               12                  1,330                1.05 (0.84--1.33)   0.649           15.8                0.289   Fixed
  Gender (male vs. female)                                11                  1,207                0.98 (0.76--1.26)   0.879           0.00                0.856   Fixed
  Tumor size (large vs. small)                            8                   1,117                1.28 (0.73--2.25)   0.386           74.5                0.000   Random
  Differentiation grade (poorly and moderately VS well)   9                   1,161                1.45 (0.95--2.21)   0.082           50.6                0.04    Random
  Lymph node metastasis (yes vs. no)                      9                   702                  1.92 (0.93--3.98)   0.049           70.0                0.001   Random
  Tumor stage (III--IV vs. I--II)                         11                  1,248                2.05 (0.99--4.27)   0.045           85.6                0.000   Random
  Depth of invasion                                       3                   292                  3.95 (2.35--6.63)   \<0.001         0.00                0.381   Fixed
  Distant metastasis                                      4                   378                  2.87 (1.60--5.16)   \<0.001         0.00                0.393   Fixed

![Association between PANDAR expression levels with clinicopathological characteristics of cancer patients. **(A)** Age, **(B)** gender, **(C)** tumor size, **(D)** differentiation grade, **(E)** lymph node metastasis, **(F)** tumor stage, **(G)** depth of invasion, **(H)** distant metastasis.](fonc-09-01337-g0006){#F6}

Sensitivity Analysis
--------------------

We performed the sensitivity analysis to evaluate the impacts of independent study on the overall outcomes. For OS, our sensitivity analysis revealed that results from Han et al. and Lu et al. had significant impacts on the outcomes, suggesting that these two studies were likely to be the main source of heterogeneity. However, after excluding single study one after another, the pooled HRs and 95% CIs list demonstrated the robustness of our results, with all pooled HRs and 95% CIs above the null hypothesis of 1.

Publication Bias
----------------

Visual inspection of the Begg funnel plot revealed asymmetry ([Figure 7A](#F7){ref-type="fig"}). This raises the possibility of publication bias, although the Begg test was not statistically significant (*z* = 1.15; *P* = 0.28). As a result, we used the trim and fill method which conservatively imputes hypothetical negative unpublished studies to mirror the positive studies that cause funnel plot asymmetry. The imputed studies produce a symmetrical funnel plot ([Figure 7B](#F7){ref-type="fig"}). The pooled analysis incorporating the hypothetical studies continued to show a statistically significant association between the high expression level of PANDAR with poor OS in malignancy patients (HR = 1.21, 95% CI 1.04--1.41, *p* = 0.012).

![Begg\'s test **(A)** and trim and fill method funnel plot **(B)** for overall survival.](fonc-09-01337-g0007){#F7}

Discussion {#s4}
==========

Cancer morbidity and mortality are rapidly growing around the world, and cancer is expected to be the leading cause of death and the most important obstacle for increasing life expectancy in every country of the world in this century ([@B3]). Although unable to translate into proteins, ncRNAs especially lncRNAs, are important in regulating growth, development, differentiation, gene expression and chromatin dynamics ([@B37], [@B38]). In the past few years, Next-Generation Sequencing(NGS) has shown that thousands of lncRNAs are abnormally expressed or mutated in various types of cancers ([@B39]). LncRNAs aberrantly expressed and mutated are closely associated with tumorigenesis, metastasis, and tumor stage ([@B40]--[@B42]). Due to its expression in certain types of cancers and its detection in circulating blood and/or urine, lncRNAs are a new kind of promising biomarkers and therapeutic targets for treating cancer with better diagnostic and prognostic value ([@B43]--[@B45]). Several cancer-associated lncRNAs which have been identified so far, are likely to be utilized as novel indicators for predicting tumor prognosis or as promising therapeutic targets for different types of cancers ([@B46]--[@B51]).

Recently, it has been found that PANDAR, as a novel tumor-associated lncRNA, exhibits abnormal expression in several cancers including gastric cancer (GC), colorectal cancer (CRC), renal cell carcinoma (RCC), bladder cancer (BC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), non-small cell lung cancer (NSCLC), and other cancers ([@B17]--[@B21], [@B32], [@B33], [@B52], [@B53]). However, inconsistent outcomes associated with PANDAR expression levels were found among several types of cancers including up-regulation in gastric cancer, hepatocellular carcinoma, colorectal cancer, thyroid cancer, osteosarcoma, breast cancer, clear cell renal cell carcinoma, and bladder cancer, whereas down-regulation in non-small cell lung cancer ([@B16]). As a kind of lncRNAs, PANDAR\'s expression level and its function can be variable in different types of cells, developmental states, and diseases, as a result of various interaction mechanisms and participating partners ([@B54]--[@B58]).

Due to the fact that the function of PANDAR in different cancers is still controversial and remains to be clarified, we conducted this meta-analysis to investigate the clinicopathological significance and prognostic value of abnormal PANDAR expression in patients suffering from cancer. Thirteen independent studies consisting of data from a total of 1,465 patients were systematically analyzed. Our results indicated that the high expression level of PANDAR was associated with poor OS significantly in cancer patients. Furthermore, we performed meta-regression and subgroup analysis to explore the sources of heterogeneity on account of the obvious heterogeneity across the studies. The outcomes of subgroup analysis showed that the prognostic significance of PANDAR was altered by the type of cancer (non-digestive system carcinoma), follow-up time (\<60 months) and paper quality (NOS scores \<7). Therefore, we could conclude that the difference in the specific type of cancer, follow-up time and paper quality was likely to be the source of heterogeneity. However, meta-regression analysis failed to identify the source of the obvious heterogeneity in above covariates. Moreover, we found that PANDAR was an independent prognostic factor of OS in cancer patients when combined with HRs from Cox multivariate analysis. PFS and DFS, defined as EFS in this meta-analysis, are important parameters that reflect tumor progression. The prognostic significance of PANDAR in EFS was also assessed in 2 studies including 194 patients. Our results showed that the association between the reduced expression level of PANDAR with poor EFS in cancer patients was not significant.

Furthermore, the prognostic value of PANDAR in certain types of cancer was evaluated. The results indicated that increased PANDAR expression was closely related to reduced OS in colorectal cancer, whereas reduced PANDAR expression was associated with decreased OS of non-small cell lung cancer. However, no significant relationship between the expression level of PANDAR and the OS of renal cell carcinoma was observed. Therefore, we could conclude that the expression level of PANDAR might play different roles in predicting OS in several kinds of cancers.

With regard to the clinicopathological characteristics, our analysis demonstrated that elevated expression level of PANDAR was associated significantly with advanced tumor stage, deeper depth of invasion, more lymph node metastasis and farther distant metastasis. However, no significant relation was found between PANDAR expression levels with older age, gender, larger tumor size and worse differentiation grade of cancer patients.

In spite of the inspiring results, there are still several disadvantages in this quantitative meta-analysis. Firstly, although the random-effect model and subgroup analysis were used, the heterogeneity among the studies was still not completely eliminated, which might bring about the bias of the results to some extent. Secondly, the cut-off value for abnormal expression of PANDAR was varied among the included studies, which could result in the bias of the outcomes. Thirdly, although the baseline figures were comparable, our summary analysis depended too much on the strength of including cohort above all, which might partially result in selection bias. Finally, some HRs could not be obtained from the included studies directly, which could make calculations from survival curves inaccurate.

Conclusions {#s5}
===========

From our study, we can conclude that elevated expression level of PANDAR may be a poor prognostic biomarker for OS. However, in this meta-analysis, there was no significant association between the expression level of PANDAR with EFS. In addition, our review revealed that elevated expression level of PANDAR was associated with decreased OS in colorectal cancer, whereas the reduced PANDAR expression level was significantly related to poor OS in non-small cell lung cancer. However, no significant relation was found between PANDAR expression level with OS of patients suffering from renal cell carcinoma. Moreover, PANDAR expression level was related to clinicopathological characteristics including TNM stage, depth of invasion, lymph node metastasis, and distant metastasis. In order to explore the more important role of PANDAR in human cancer, more relevant researches will be needed in the future.
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GC

:   gastric cancer

CRC

:   colorectal cancer

RCC

:   renal cell carcinoma

BC

:   bladder cancer

HCC

:   hepatocellular carcinoma

CCA

:   cholangiocarcinoma

NSCLC

:   non-small cell lung cancer

HR

:   hazard ratios

OR

:   Odds ratios

CI

:   confidence intervals

OS

:   overall survival

PFS

:   progression-free survival

DFS

:   disease-free survival
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:   western blot
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:   polymerase chain reaction

IHC

:   immunohistochemistry
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